Novartis AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
Phase 3
Completed
- Conditions
- HYPERTENSION
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00170976
- Locations
- π©πͺ
Sites in germany, Multiple Locations, Germany
π¨πNovartis Pharmaceuticals, Basel, Switzerland
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 250
- Registration Number
- NCT00171405
- Locations
- π¬π§
Investigative Site, London, United Kingdom
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
Phase 3
Completed
- Conditions
- Traumatic Brain Injury
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 67
- Registration Number
- NCT00171795
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
Phase 4
Completed
- Conditions
- HypertensionDyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 213
- Registration Number
- NCT00171327
- Locations
- π·πΊ
Novartis, Moscow, Russian Federation
Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2714
- Registration Number
- NCT00170989
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
Phase 4
Completed
- Conditions
- Diastolic DysfunctionHypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT00170924
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Comparison of Two Treatment Strategies in Hypertensive Patients
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4445
- Registration Number
- NCT00171444
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00171535
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- Heterozygous Familial HypercholesterolemiaMixed Dyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 84
- Registration Number
- NCT00171236
- Locations
- π¨π
Novartis, Basel, Switzerland
Antialbuminuric Effects of Valsartan and Lisinopril
Phase 4
Terminated
- Conditions
- HypertensionEarly Diabetic Nephropathy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171600
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
Β© Copyright 2025. All Rights Reserved by MedPath